ImmunityBio Investors Nab Initial OK On Derivative Suit Deal
By Sydney Price · July 30, 2025, 6:12 PM EDT
A California federal judge has granted initial approval to a deal ending derivative claims that ImmunityBio executives failed to disclose manufacturing deficiencies that doomed the company's lead cancer drug application....
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login